Every 8-K that GINKGO BIOWORKS HLDGS WTS (DNABW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DNABW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNABW filings page.
Ginkgo Bioworks Holdings, Inc. reported second quarter 2026 revenue of $20 million, down 48% from $39 million a year earlier, reflecting program rationalization from restructuring. Net loss from continuing operations was $(57) million, versus $(53) million in the prior-year quarter, and Adjusted EBITDA was $(36) million, down from $(25) million. Cash, cash equivalents and marketable securities totaled $302 million as of June 30, 2026, and the company reaffirmed full-year 2026 cash burn guidance of ($150)-($125) million.
Strategically, Ginkgo highlighted growth in autonomous lab infrastructure. It won government-backed contracts to build cloud labs at Caltech, Northwestern, the University of Maryland and a $47 million, 97-instrument autonomous lab for EMSL at Pacific Northwest National Laboratory, while continuing to scale its Nebula facility. Its new ADME-One pharma service, positioned as 10x cheaper than WuXi, signed 17 customers in its first six weeks.
Ginkgo Bioworks Holdings, Inc. plans to host a presentation and Q&A session reviewing its business performance for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, beginning at 4:30 p.m. ET.
The session will be webcast via Ginkgo's investor relations website, with a replay available. Shareholders may submit questions in advance via X to @Ginkgo using hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com. The company highlights its websites, blog, news site, and social media channels as outlets for potentially material information.
Ginkgo Bioworks Holdings, Inc. completed the sale of substantially all operations of its Biosecurity segment to Tower Biosecurity, Inc. on April 3, 2026. In return, Ginkgo received common stock representing approximately 20% of Tower Biosecurity’s fully diluted equity, which will be accounted for under the equity method.
Because this deal represents a strategic shift, Biosecurity’s historical results will be reported as discontinued operations. Unaudited pro forma statements show how Ginkgo’s balance sheet and results for 2023–2025 would look without Biosecurity, with lower revenue but slightly reduced net losses over all three years.
Ginkgo Bioworks Holdings, Inc. reported weaker 2025 revenue alongside significantly reduced losses and a major strategic shift. Total revenue for 2025 was $170.2 million, down from $227.0 million (a 25% decline), with Cell Engineering revenue falling to $132.7 million and Biosecurity revenue to $37.4 million. Despite this, the GAAP net loss narrowed sharply to $(312.8) million from $(547.0) million, and Adjusted EBITDA improved to $(167.0) million from $(293.3) million, reflecting lower operating expenses and restructuring benefits.
The company ended 2025 with $423 million in cash, cash equivalents and marketable securities, down from higher prior-year levels, and guided for 2026 total cash burn of $(150)–$(125) million. Ginkgo plans to divest its non‑core biosecurity business to investors in exchange for a minority equity stake, turning it into a standalone private company, while refocusing the business on autonomous labs. Management highlighted expansion of its frontier autonomous lab in Boston, new collaboration results with OpenAI showing a 40% improvement in cell‑free protein synthesis, and a $47 million autonomous lab contract with Pacific Northwest National Laboratory as key proof points for the new strategy.
Ginkgo Bioworks Holdings, Inc. reported a leadership transition in its operating roles. Effective January 1, 2026, co‑founder Dr. Reshma Shetty will transition her Chief Operating Officer responsibilities to Chief Executive Officer Dr. Jason Kelly and executive Jennifer Wipf. Dr. Shetty will remain President, continue serving on the Board of Directors, and focus on expanding and using the company’s autonomous lab to deliver cell engineering service offerings, while Dr. Kelly will take on the principal operating officer policymaking duties.
Jennifer Wipf, previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will oversee operations functions such as day‑to‑day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly. The changes keep Dr. Shetty in a substantial policymaking role while formalizing broader operating responsibilities for Dr. Kelly and Ms. Wipf.
Ginkgo Bioworks (DNA) furnished an 8-K announcing it issued a press release with its financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The filing, dated November 6, 2025, is an administrative disclosure under Item 2.02 (Results of Operations and Financial Condition) and includes the Inline XBRL cover page file as Exhibit 104.